Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Interstitial Lung Disease (ILD): early-phase trial registry
1 of 2 indexed Interstitial Lung Disease (ILD) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Interstitial Lung Disease (ILD): 2 US clinical trials tracked, 1 recruiting.
Interstitial Lung Disease (ILD) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Pulmovant, running 1 of these trials.
Enrollment posture brief
Registry condition interstitial-lung-disease-ild
OPEN 1 | RECR 50% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Interstitial Lung Disease (ILD) lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Interstitial Lung Disease (ILD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Interstitial Lung Disease (ILD) is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
Pulmovant
NCT07333183
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Tempus AI
NCT06911632
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Named interventions
Most-linked intervention names on Interstitial Lung Disease (ILD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Interstitial Lung Disease (ILD) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Interstitial Lung Disease (ILD) page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Interstitial Lung Disease (ILD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pulmovant sponsors the most Interstitial Lung Disease (ILD) trials on record, review their full trial history before evaluating a specific study. See Pulmovant's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Interstitial Lung Disease (ILD) condition card totals 2 registered trials; most-linked intervention ECG-based AI Device - Results Not Returned to Investigator; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.